TRACON Pharmaceuticals reports positive results from Phase Ib/II trial of HCC drug

TRACON Pharmaceuticals has reported positive results from the National Cancer Institute (NCI) Phase Ib/II clinical trial of TRC105 and Nexavar (sorafenib) to treat patients with hepatocellular cancer (HCC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news